 | |
| Legal status | |
|---|---|
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C26H25NO |
| Molar mass | 367.492 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
JWH-145 (1-naphthalenyl(1-pentyl-5-phenyl-1H-pyrrol-3-yl)-methanone) is asynthetic cannabinoid from the naphthoylpyrrole family which acts as an agonist of theCB1 (Ki = 14 ± 2nM) andCB2 (Ki = 6.4 ± 0.4nM) receptors, with a moderate (~2.2x) selectivity for the CB2 receptor. JWH-145 was first synthesized in 2006 byJohn W. Huffman and colleagues to examine the nature of ligand binding to theCB1 receptor.[1]
In the United States JWH-145 is not federally scheduled, although some states have passed legislation banning the sale, possession, and manufacture of JWH-145.[2][3][4][5]
In Canada, JWH-145 and other naphthoylpyrrole-based cannabinoids are Schedule II controlled substances under theControlled Drugs and Substances Act.[citation needed]
In the United Kingdom, JWH-145 and other naphthoylpyrrole-based cannabinoids are considered Class B drugs under theMisuse of Drugs Act 1971.[citation needed]
 | Thiscannabinoid related article is astub. You can help Wikipedia byexpanding it. |
